SYSTEMATIC REVIEW article
Front. Oncol.
Sec. Gynecological Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1561836
Risk Factors for Lower Limb Lymphedema After Gynecological Cancer Treatment: A Systematic Review
Provisionally accepted- 1Ghent University Hospital, Ghent, Belgium
- 2Ghent University, Ghent, East Flanders, Belgium
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: As treatments in gynecological cancer improve, the number of cancer survivors increases, with more patients facing long-term side effects of their treatment. One debilitating side effect is lower limb lymphedema (LLL). Unlike upper limb lymphedema (ULL), diagnosis of LLL remains challenging due to the absence of a clear definition, bilateral presentation complicating comparison, and confusion with post-operative weight changes. This systematic review investigated incidences and risk factors for LLL.Methods: We systematically searched PubMed, Embase, and CENTRAL databases for articles on LLL following treatment for pelvic gynecological cancer from 1979 to November 2024. Two independent researchers extracted data, based on predefined inclusion and exclusion criteria. We assessed bias using the Risk of Bias in Non-Randomized Studies (ROBINS-I) tool and adhered to PRISMA reporting guidelines.Results: Our review included 46 studies, with incidence rates varying widely across cancer types: 7.4-55.9% in cervical cancer, 1.2-47% in endometrial cancer, 5.6-30.4% in ovarian cancer, and 10.1-43% in vulvar cancer. Several risk factors for LLL emerged. Notably, lymphadenectomy, the number of removed lymph nodes, radiotherapy, and a body mass index (BMI) exceeding 25 kg/m² were significant risk factors. Surgical technique did not impact LLL risk. Conclusion: LLL frequently occurs following gynecological cancer treatments, emphasizing the importance of careful monitoring and proactive management in clinical settings. Overall, the findings highlight the complexity and variability in risk factors for LLL across different gynecological cancers. The significant heterogeneity in study designs, populations, and methodologies underscores the need for standardized approaches in future research to better understand and mitigate the risk of LLL in these patients.
Keywords: gynecological cancer, Risk factors, Lower extremity lymphedema, review, Incidence
Received: 16 Jan 2025; Accepted: 25 Apr 2025.
Copyright: © 2025 Decorte, Cerckel, Kheir, Monten, Vandecasteele, Vanden Bossche, Pauwels and Randon. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Tina Decorte, Ghent University Hospital, Ghent, Belgium
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.